Biotech News

PharmaCyte Biotech Reports Strong Cash and Asset Position

PharmaCyte Biotech (PMCB)PharmaCyte BiotechFDA / regulatory

As reported in its Form 10-Q for the latest quarter, the Company maintains more than $17 million in cash with total assets over $36 million

LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) today provided an update on its financial position. As reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 (PMCB’s fiscal year ends April 30), PharmaCyte held total assets of approximately $36.7 million, including approximately $17.7 million in cash and cash equivalents. Stockholders’ equity totaled approximately $27.5 million as of July 31, 2026. PharmaCyte has approximately 566,000 shares of common stock outstanding.

“Our balance sheet is the foundation of PharmaCyte’s strategy,” said Josh Silverman, PharmaCyte Chief Executive Officer. “With $17.7 million in cash and more than $36 million in total assets, we have the capital to deploy with discipline and to pursue opportunities designed to create value for our shareholders.”

PharmaCyte plans to continue pursuing value-accretive investment opportunities and disciplined operational management to further enhance shareholder returns.

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) is a biotechnology company focused on developing cellular therapies for cancer, diabetes and other serious diseases. In parallel, the Company employs a disciplined investment strategy designed to strengthen its financial position and maximize shareholder value through strategic cash deployment.

Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of PharmaCyte’s management and Board of Directors. Any statements contained in this press release which do not describe historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, whether our exploration of additional opportunities to create new paths toward shareholder value is successful, the effect of the reverse stock split on the market price and liquidity of our common stock and our ability to regain and maintain compliance with Nasdaq listing requirements, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise. More information about PharmaCyte Biotech can be found at https://pharmacyte.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20261113547352/en/

Investor Contact: CORE IR

[email protected]

Media Contact: Jules Abraham

CORE IR

516.222.2560

[email protected]

Source: PharmaCyte Biotech, Inc.

Related news

IDYAIDEAYA Biosciences2026-11-16 21:05 EST

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

PMCBPharmaCyte Biotech2026-11-11 14:00 EST

PharmaCyte Biotech, Inc. Announces Reverse Stock Split

RVMDRevolution Medicines2026-11-16 18:00 EST

European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

TEVATeva Pharmaceutical Industries2026-11-16 13:00 EST

U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

BLTEBelite Bio2026-10-19 10:00 EST

Belite Bio Announces Uplisting to the Nasdaq Global Select Market

LEGNLegend Biotech Corporation2026-10-15 12:00 EST

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

REGNRegeneron Pharmaceuticals2026-11-18 23:03 EST

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

GSKGSK plc2026-11-17 18:50 EST

Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer

REGNRegeneron Pharmaceuticals2026-11-17 12:00 EST

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications

PharmaCyte Biotech

PharmaCyte Biotech was a biotechnology company focused on cell encapsulation and oncology before its restructuring and public-market decline. Its story centered on an experimental cancer-delivery platform.

Recent company news

Stock data

Close
4.56 USD
Market cap
8.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States